Published in Semin Immunopathol on August 01, 2014
Novel therapeutic targets in primary biliary cirrhosis. Nat Rev Gastroenterol Hepatol (2015) 1.01
Innate immunity drives the initiation of a murine model of primary biliary cirrhosis. PLoS One (2015) 0.84
Immunological potential of cytotoxic T lymphocyte antigen 4 immunoglobulin in murine autoimmune cholangitis. Clin Exp Immunol (2015) 0.80
The cumulative effects of known susceptibility variants to predict primary biliary cirrhosis risk. Genes Immun (2015) 0.77
Xenobiotics and loss of tolerance in primary biliary cholangitis. World J Gastroenterol (2016) 0.76
CYP2E1 autoantibodies in liver diseases. Redox Biol (2014) 0.76
The role of natural killer T cells in a mouse model with spontaneous bile duct inflammation. Physiol Rep (2017) 0.75
NK Cell Subtypes as Regulators of Autoimmune Liver Disease. Gastroenterol Res Pract (2016) 0.75
The Role of Genetic and Immune Factors for the Pathogenesis of Primary Sclerosing Cholangitis in Childhood. Gastroenterol Res Pract (2016) 0.75
Why Doesn't Primary Biliary Cholangitis Respond to Immunosuppressive Medications? Curr Hepatol Rep (2017) 0.75
[Chronic cholestatic liver diseases : Differential diagnosis, pathogenesis and current treatment in adults]. Internist (Berl) (2017) 0.75
Crosstalk between type II NKT cells and T cells leads to spontaneous chronic inflammatory liver disease. J Hepatol (2017) 0.75
Pathogen recognition and innate immunity. Cell (2006) 44.14
A blast from the past: clearance of apoptotic cells regulates immune responses. Nat Rev Immunol (2002) 8.79
ATP drives lamina propria T(H)17 cell differentiation. Nature (2008) 8.02
Primary biliary cirrhosis. N Engl J Med (2005) 7.59
Control of TH17 cells occurs in the small intestine. Nature (2011) 4.03
Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. N Engl J Med (2009) 3.70
FOXP3+ regulatory T cells in autoimmune hepatitis are fully functional and not reduced in frequency. J Hepatol (2012) 3.57
Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. Nat Genet (2010) 3.15
Human MAIT cells are xenobiotic-resistant, tissue-targeted, CD161hi IL-17-secreting T cells. Blood (2010) 3.06
Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis. Nat Genet (2011) 3.06
Interplay between the TH17 and TReg cell lineages: a (co-)evolutionary perspective. Nat Rev Immunol (2009) 2.65
Primary biliary cirrhosis in monozygotic and dizygotic twins: genetics, epigenetics, and environment. Gastroenterology (2004) 2.64
Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice. Gastroenterology (2012) 2.58
The cholangiopathies: disorders of biliary epithelia. Gastroenterology (2004) 2.38
p-ANCAs in autoimmune liver disorders recognise human beta-tubulin isotype 5 and cross-react with microbial protein FtsZ. Gut (2009) 2.20
Mechanisms of disease: a 'DAMP' view of inflammatory arthritis. Nat Clin Pract Rheumatol (2007) 2.18
The plasticity and stability of regulatory T cells. Nat Rev Immunol (2013) 2.15
Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology (2005) 2.15
Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology (2004) 2.02
Identification of HLA-A2-restricted CD8(+) cytotoxic T cell responses in primary biliary cirrhosis: T cell activation is augmented by immune complexes cross-presented by dendritic cells. J Exp Med (2002) 2.00
Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases. Hepatology (2001) 1.92
IL-2 receptor alpha(-/-) mice and the development of primary biliary cirrhosis. Hepatology (2006) 1.91
Loss of inositol 1,4,5-trisphosphate receptors from bile duct epithelia is a common event in cholestasis. Gastroenterology (2003) 1.91
Concurrent autoimmune diseases in patients with autoimmune hepatitis. J Clin Gastroenterol (2010) 1.86
Dense fine-mapping study identifies new susceptibility loci for primary biliary cirrhosis. Nat Genet (2012) 1.85
Regulatory T cells in patients with systemic lupus erythematosus. J Autoimmun (2006) 1.83
Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nat Genet (2013) 1.83
Primary sclerosing cholangitis and disease distribution in inflammatory bowel disease. Clin Gastroenterol Hepatol (2011) 1.77
Breaking tolerance to the natural human liver autoantigen cytochrome P450 2D6 by virus infection. J Exp Med (2008) 1.76
Aberrant homing of mucosal T cells and extra-intestinal manifestations of inflammatory bowel disease. Nat Rev Immunol (2006) 1.71
Functional study of CD4+CD25+ regulatory T cells in health and autoimmune hepatitis. J Immunol (2006) 1.70
Genome-wide association analysis in primary sclerosing cholangitis. Gastroenterology (2009) 1.69
Quantitative and functional analysis of PDC-E2-specific autoreactive cytotoxic T lymphocytes in primary biliary cirrhosis. J Clin Invest (2002) 1.65
Mycoplasma antigens as a possible trigger for the induction of antimitochondrial antibodies in primary biliary cirrhosis. Liver Int (2009) 1.62
Variants at IRF5-TNPO3, 17q12-21 and MMEL1 are associated with primary biliary cirrhosis. Nat Genet (2010) 1.62
HLA DRB4 0101-restricted immunodominant T cell autoepitope of pyruvate dehydrogenase complex in primary biliary cirrhosis: evidence of molecular mimicry in human autoimmune diseases. J Exp Med (1995) 1.61
Immunohistochemical characterization of hepatic lymphocytes in primary biliary cirrhosis in comparison with primary sclerosing cholangitis and autoimmune chronic active hepatitis. Mayo Clin Proc (1993) 1.59
Primary sclerosing cholangitis. Lancet (2013) 1.59
Enhanced innate immune responsiveness and intolerance to intestinal endotoxins in human biliary epithelial cells contributes to chronic cholangitis. Liver Int (2011) 1.57
Impairment of CD4(+)CD25(+) regulatory T-cells in autoimmune liver disease. J Hepatol (2004) 1.54
Connecting liver and gut: murine liver sinusoidal endothelium induces gut tropism of CD4+ T cells via retinoic acid. Hepatology (2012) 1.53
Biliary apotopes and anti-mitochondrial antibodies activate innate immune responses in primary biliary cirrhosis. Hepatology (2010) 1.53
Liver/kidney microsomal antibody type 1 targets CYP2D6 on hepatocyte plasma membrane. Gut (2000) 1.53
Liver-targeted and peripheral blood alterations of regulatory T cells in primary biliary cirrhosis. Hepatology (2006) 1.53
Genetic distinctions between types 1 and 2 autoimmune hepatitis. Am J Gastroenterol (1997) 1.49
MAdCAM-1 expressed in chronic inflammatory liver disease supports mucosal lymphocyte adhesion to hepatic endothelium (MAdCAM-1 in chronic inflammatory liver disease). Hepatology (2001) 1.47
Adoptive transfer of CD8(+) T cells from transforming growth factor beta receptor type II (dominant negative form) induces autoimmune cholangitis in mice. Hepatology (2008) 1.45
Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci. Nat Genet (2010) 1.43
Hepatic endothelial CCL25 mediates the recruitment of CCR9+ gut-homing lymphocytes to the liver in primary sclerosing cholangitis. J Exp Med (2004) 1.43
Function and pathophysiological importance of ABCB4 (MDR3 P-glycoprotein). Pflugers Arch (2006) 1.43
MDR3 (ABCB4) defects: a paradigm for the genetics of adult cholestatic syndromes. Semin Liver Dis (2007) 1.42
The immunobiology and pathophysiology of primary biliary cirrhosis. Annu Rev Pathol (2013) 1.41
Identification of 2-nonynoic acid, a cosmetic component, as a potential trigger of primary biliary cirrhosis. J Autoimmun (2006) 1.41
Bcl-2-dependent oxidation of pyruvate dehydrogenase-E2, a primary biliary cirrhosis autoantigen, during apoptosis. J Clin Invest (2001) 1.40
Imbalance between T helper type 17 and T regulatory cells in patients with primary biliary cirrhosis: the serum cytokine profile and peripheral cell population. Clin Exp Immunol (2009) 1.40
Altered monocyte responses to defined TLR ligands in patients with primary biliary cirrhosis. Hepatology (2005) 1.37
The X and why of xenobiotics in primary biliary cirrhosis. J Autoimmun (2007) 1.36
HLA class II haplotypes in primary sclerosing cholangitis patients from five European populations. Tissue Antigens (1999) 1.35
HLA class II alleles, genotypes, haplotypes, and amino acids in primary biliary cirrhosis: a large-scale study. Hepatology (2006) 1.33
Genome-wide association study identifies TNFSF15 and POU2AF1 as susceptibility loci for primary biliary cirrhosis in the Japanese population. Am J Hum Genet (2012) 1.32
The 210-kD nuclear envelope polypeptide recognized by human autoantibodies in primary biliary cirrhosis is the major glycoprotein of the nuclear pore. J Clin Invest (1990) 1.32
Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants. Hum Mol Genet (2012) 1.32
Periductal interleukin-17 production in association with biliary innate immunity contributes to the pathogenesis of cholangiopathy in primary biliary cirrhosis. Clin Exp Immunol (2009) 1.31
Lithocholic acid feeding induces segmental bile duct obstruction and destructive cholangitis in mice. Am J Pathol (2006) 1.30
Extended analysis of a genome-wide association study in primary sclerosing cholangitis detects multiple novel risk loci. J Hepatol (2012) 1.29
Gut homing receptors on CD8 T cells are retinoic acid dependent and not maintained by liver dendritic or stellate cells. Gastroenterology (2009) 1.29
Interleukin-17 contributes to the pathogenesis of autoimmune hepatitis through inducing hepatic interleukin-6 expression. PLoS One (2011) 1.27
Lipopolysaccharide disrupts tight junctions in cholangiocyte monolayers by a c-Src-, TLR4-, and LBP-dependent mechanism. Am J Physiol Gastrointest Liver Physiol (2007) 1.26
The genetics of complex cholestatic disorders. Gastroenterology (2013) 1.24
Death receptor 5 mediated-apoptosis contributes to cholestatic liver disease. Proc Natl Acad Sci U S A (2008) 1.24
A sensitive bead assay for antimitochondrial antibodies: Chipping away at AMA-negative primary biliary cirrhosis. Hepatology (2007) 1.23
Lipopolysaccharide causes an increase in intestinal tight junction permeability in vitro and in vivo by inducing enterocyte membrane expression and localization of TLR-4 and CD14. Am J Pathol (2012) 1.22
Biliary epithelial cell antibodies link adaptive and innate immune responses in primary sclerosing cholangitis. Gastroenterology (2007) 1.20
Influence of dominant bile duct stenoses and biliary infections on outcome in primary sclerosing cholangitis. J Hepatol (2009) 1.19
Increased killing activity and decreased cytokine production in NK cells in patients with primary biliary cirrhosis. J Autoimmun (2006) 1.17
Mechanisms of environmental influence on human autoimmunity: a National Institute of Environmental Health Sciences expert panel workshop. J Autoimmun (2012) 1.16
Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis. Hepatology (2006) 1.15
IL-12/Th1 and IL-23/Th17 biliary microenvironment in primary biliary cirrhosis: implications for therapy. Hepatology (2014) 1.15
Genetic susceptibilities for immune expression and liver cell injury in autoimmune hepatitis. Immunol Rev (2000) 1.15
Do antinuclear antibodies in primary biliary cirrhosis patients identify increased risk for liver failure? Clin Gastroenterol Hepatol (2004) 1.14
Phylogenetic and immunological definition of four lipoylated proteins from Novosphingobium aromaticivorans, implications for primary biliary cirrhosis. J Autoimmun (2005) 1.14
IL-17A plays a critical role in the pathogenesis of liver fibrosis through hepatic stellate cell activation. J Immunol (2013) 1.14
The dynamic biliary epithelia: molecules, pathways, and disease. J Hepatol (2012) 1.13
Heterogeneity of autoreactive T cell clones specific for the E2 component of the pyruvate dehydrogenase complex in primary biliary cirrhosis. J Exp Med (1995) 1.11
Etiopathogenesis of primary sclerosing cholangitis. Semin Liver Dis (2006) 1.11
Genome-wide association analysis in primary sclerosing cholangitis and ulcerative colitis identifies risk loci at GPR35 and TCF4. Hepatology (2013) 1.11
A multifaceted imbalance of T cells with regulatory function characterizes type 1 autoimmune hepatitis. Hepatology (2010) 1.10
Three ulcerative colitis susceptibility loci are associated with primary sclerosing cholangitis and indicate a role for IL2, REL, and CARD9. Hepatology (2011) 1.09
Cholangiocyte N-Ras protein mediates lipopolysaccharide-induced interleukin 6 secretion and proliferation. J Biol Chem (2011) 1.07
Microbial mimics are major targets of crossreactivity with human pyruvate dehydrogenase in primary biliary cirrhosis. J Hepatol (2004) 1.06
Relation between Escherichia coli R(rough)-forms in gut, lipid A in liver, and primary biliary cirrhosis. Lancet (1989) 1.05
Formiminotransferase cyclodeaminase is an organ-specific autoantigen recognized by sera of patients with autoimmune hepatitis. Gastroenterology (1999) 1.05
Toll-like receptors in liver fibrosis: cellular crosstalk and mechanisms. Front Physiol (2012) 1.05
A murine model of type 2 autoimmune hepatitis: Xenoimmunization with human antigens. Hepatology (2004) 1.05
Pathogenesis of primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol (2011) 1.04
Genetics of liver disease: immunogenetics and disease pathogenesis. Gut (2004) 1.04
Review article: overlap syndromes and autoimmune liver disease. Aliment Pharmacol Ther (2012) 1.03
T cell targeting and phagocytosis of apoptotic biliary epithelial cells in primary biliary cirrhosis. J Autoimmun (2007) 1.03
Autoantibodies and their antigens in autoimmune hepatitis. Semin Liver Dis (2009) 1.02
Regulation of mucosal addressin cell adhesion molecule 1 expression in human and mice by vascular adhesion protein 1 amine oxidase activity. Hepatology (2011) 1.02
C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med (2004) 15.30
C-reactive protein: a critical update. J Clin Invest (2003) 11.77
Primary biliary cirrhosis. N Engl J Med (2005) 7.59
Primary biliary cirrhosis. Hepatology (2009) 5.35
Targeting C-reactive protein for the treatment of cardiovascular disease. Nature (2006) 4.07
Pathogenesis and natural history of osteonecrosis. Semin Arthritis Rheum (2002) 3.30
Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma. Nat Genet (2011) 3.18
Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. Nat Genet (2010) 3.15
Autoimmune acute liver failure: proposed clinical and histological criteria. Hepatology (2011) 2.64
Primary biliary cirrhosis in monozygotic and dizygotic twins: genetics, epigenetics, and environment. Gastroenterology (2004) 2.64
Liver autoimmunity triggered by microbial activation of natural killer T cells. Cell Host Microbe (2008) 2.30
Anti-mitochondrial antibodies and primary biliary cirrhosis in TGF-beta receptor II dominant-negative mice. J Immunol (2006) 2.18
Bacterial CpG induces hyper-IgM production in CD27(+) memory B cells in primary biliary cirrhosis. Gastroenterology (2005) 2.17
NOD.c3c4 congenic mice develop autoimmune biliary disease that serologically and pathogenetically models human primary biliary cirrhosis. J Exp Med (2006) 2.16
Frequency of monosomy X in women with primary biliary cirrhosis. Lancet (2004) 2.13
Deletion of interleukin-12p40 suppresses autoimmune cholangitis in dominant negative transforming growth factor beta receptor type II mice. Hepatology (2009) 2.11
Loss of tolerance in C57BL/6 mice to the autoantigen E2 subunit of pyruvate dehydrogenase by a xenobiotic with ensuing biliary ductular disease. Hepatology (2008) 2.05
Identification of HLA-A2-restricted CD8(+) cytotoxic T cell responses in primary biliary cirrhosis: T cell activation is augmented by immune complexes cross-presented by dendritic cells. J Exp Med (2002) 2.00
Antimitochondrial antibodies in acute liver failure: implications for primary biliary cirrhosis. Hepatology (2007) 1.93
IL-2 receptor alpha(-/-) mice and the development of primary biliary cirrhosis. Hepatology (2006) 1.91
Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nat Genet (2013) 1.83
Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. J Hepatol (2010) 1.80
Probiotics and immunity. J Gastroenterol (2009) 1.79
Deletion of interleukin (IL)-12p35 induces liver fibrosis in dominant-negative TGFβ receptor type II mice. Hepatology (2013) 1.78
Quantitation and phenotypic analysis of natural killer T cells in primary biliary cirrhosis using a human CD1d tetramer. Gastroenterology (2002) 1.72
CXCR5+ CD4+ T follicular helper cells participate in the pathogenesis of primary biliary cirrhosis. Hepatology (2015) 1.70
Lack of immunological or molecular evidence for a role of mouse mammary tumor retrovirus in primary biliary cirrhosis. Gastroenterology (2004) 1.67
Repair-related activation of hedgehog signaling promotes cholangiocyte chemokine production. Hepatology (2009) 1.65
Quantitative and functional analysis of PDC-E2-specific autoreactive cytotoxic T lymphocytes in primary biliary cirrhosis. J Clin Invest (2002) 1.65
Diverse roles of invariant natural killer T cells in liver injury and fibrosis induced by carbon tetrachloride. Hepatology (2009) 1.61
The role of environmental factors in primary biliary cirrhosis. Trends Immunol (2009) 1.61
Respiratory syncytial virus--a comprehensive review. Clin Rev Allergy Immunol (2013) 1.57
Hepatic IL-17 responses in human and murine primary biliary cirrhosis. J Autoimmun (2008) 1.57
Antimitochondrial antibodies and reactivity to N. aromaticivorans proteins in Icelandic patients with primary biliary cirrhosis and their relatives. Am J Gastroenterol (2004) 1.57
The geoepidemiology of systemic lupus erythematosus. Autoimmun Rev (2009) 1.57
Regulatory T cells: development, function and role in autoimmunity. Autoimmun Rev (2005) 1.57
The unfinished business of primary biliary cirrhosis. J Hepatol (2008) 1.56
Apotopes and the biliary specificity of primary biliary cirrhosis. Hepatology (2009) 1.55
Biliary apotopes and anti-mitochondrial antibodies activate innate immune responses in primary biliary cirrhosis. Hepatology (2010) 1.53
Cytochrome P450 2A6: a new hepatic autoantigen in patients with chronic hepatitis C virus infection. J Hepatol (2003) 1.53
Heterogeneity of dendritic cells in the mouse liver: identification and characterization of four distinct populations. J Immunol (2003) 1.53
Liver-targeted and peripheral blood alterations of regulatory T cells in primary biliary cirrhosis. Hepatology (2006) 1.53
Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis. Hepatology (2014) 1.51
The SAPHO syndrome. Semin Arthritis Rheum (2012) 1.50
Inflamm-aging: autoimmunity, and the immune-risk phenotype. Autoimmun Rev (2004) 1.50
The specificity of fatigue in primary biliary cirrhosis: evaluation of a large clinic practice. Hepatology (2010) 1.49
Genes and goals: an approach to microarray analysis in autoimmunity. Autoimmun Rev (2005) 1.48
Twin studies in autoimmune disease: genetics, gender and environment. J Autoimmun (2011) 1.48
Pathogenesis of cholestatic liver disease and therapeutic approaches. Gastroenterology (2010) 1.47
Chemical xenobiotics and mitochondrial autoantigens in primary biliary cirrhosis: identification of antibodies against a common environmental, cosmetic, and food additive, 2-octynoic acid. J Immunol (2005) 1.47
Patients with primary biliary cirrhosis react against a ubiquitous xenobiotic-metabolizing bacterium. Hepatology (2003) 1.46
Identifying opportunities to improve management of autoimmune hepatitis: evaluation of drug adherence and psychosocial factors. J Hepatol (2012) 1.46
Adoptive transfer of CD8(+) T cells from transforming growth factor beta receptor type II (dominant negative form) induces autoimmune cholangitis in mice. Hepatology (2008) 1.45
IL-2 receptor alpha deficiency and features of primary biliary cirrhosis. J Autoimmun (2006) 1.43
X chromosome monosomy: a common mechanism for autoimmune diseases. J Immunol (2005) 1.41
A dietary restriction influences the progression but not the initiation of MSG-Induced nonalcoholic steatohepatitis. J Med Food (2014) 1.41
Primary biliary cirrhosis is associated with altered hepatic microRNA expression. J Autoimmun (2009) 1.41
The immunobiology and pathophysiology of primary biliary cirrhosis. Annu Rev Pathol (2013) 1.41
Identification of 2-nonynoic acid, a cosmetic component, as a potential trigger of primary biliary cirrhosis. J Autoimmun (2006) 1.41
Human leukocyte antigen polymorphisms in Italian primary biliary cirrhosis: a multicenter study of 664 patients and 1992 healthy controls. Hepatology (2008) 1.40
Anti-kelch-like 12 and anti-hexokinase 1: novel autoantibodies in primary biliary cirrhosis. Liver Int (2014) 1.40
Apocalypsal versus apocryphal: the role of retroviruses in primary biliary cirrhosis. Am J Gastroenterol (2004) 1.39
The retroviral myth of primary biliary cirrhosis: is this (finally) the end of the story? J Hepatol (2009) 1.39
IgG4-related sclerosing disease: autoimmune pancreatitis and extrapancreatic manifestations. Radiographics (2011) 1.38
Primary biliary cirrhosis. Lancet (2011) 1.37
Altered monocyte responses to defined TLR ligands in patients with primary biliary cirrhosis. Hepatology (2005) 1.37
The X and why of xenobiotics in primary biliary cirrhosis. J Autoimmun (2007) 1.36
Lupus nephritis: a critical review. Autoimmun Rev (2012) 1.36
Is autoimmunity a matter of sex? Autoimmun Rev (2008) 1.35
Myeloid STAT3 inhibits T cell-mediated hepatitis by regulating T helper 1 cytokine and interleukin-17 production. Gastroenterology (2009) 1.34
Stevens-Johnson syndrome and toxic epidermal necrolysis. Autoimmun Rev (2008) 1.33
Steroid induced osteonecrosis: An analysis of steroid dosing risk. Autoimmun Rev (2010) 1.33
Therapeutic effect of cytotoxic T lymphocyte antigen 4/immunoglobulin on a murine model of primary biliary cirrhosis. Hepatology (2013) 1.33
Inflammation and endothelial function: direct vascular effects of human C-reactive protein on nitric oxide bioavailability. Circulation (2005) 1.33
Mushrooms, tumors, and immunity: an update. Exp Biol Med (Maywood) (2004) 1.32
Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants. Hum Mol Genet (2012) 1.32
Natural killer T cells exacerbate liver injury in a transforming growth factor beta receptor II dominant-negative mouse model of primary biliary cirrhosis. Hepatology (2008) 1.30
The implications of autoimmunity and pregnancy. J Autoimmun (2009) 1.28
Giant cell arteritis: a review of classification, pathophysiology, geoepidemiology and treatment. Autoimmun Rev (2012) 1.26
The emergence of progressive multifocal leukoencephalopathy (PML) in rheumatic diseases. J Autoimmun (2008) 1.25
Transgenic human CRP is not pro-atherogenic, pro-atherothrombotic or pro-inflammatory in apoE-/- mice. Atherosclerosis (2007) 1.24
The consequences of apoptosis in autoimmunity. J Autoimmun (2008) 1.24
The X chromosome and immune associated genes. J Autoimmun (2011) 1.24
Female predominance and X chromosome defects in autoimmune diseases. J Autoimmun (2009) 1.24
The regulatory, inflammatory, and T cell programming roles of interleukin-2 (IL-2). J Autoimmun (2008) 1.24
A sensitive bead assay for antimitochondrial antibodies: Chipping away at AMA-negative primary biliary cirrhosis. Hepatology (2007) 1.23
Surviving the butterfly and the wolf: mortality trends in systemic lupus erythematosus. Autoimmun Rev (2004) 1.22
From bases to basis: linking genetics to causation in primary biliary cirrhosis. Clin Gastroenterol Hepatol (2005) 1.22
The immunobiology of systemic sclerosis. Semin Arthritis Rheum (2008) 1.22
Interferon alpha and its contribution to autoimmunity. Curr Opin Investig Drugs (2006) 1.21
Clinical significance of complement deficiencies. Ann N Y Acad Sci (2009) 1.21
Cross-talk between aryl hydrocarbon receptor and the inflammatory response: a role for nuclear factor-κB. J Biol Chem (2013) 1.21
Immunization with a xenobiotic 6-bromohexanoate bovine serum albumin conjugate induces antimitochondrial antibodies. J Immunol (2003) 1.21
Drugs and autoimmunity--a contemporary review and mechanistic approach. J Autoimmun (2009) 1.21
Definition of human autoimmunity--autoantibodies versus autoimmune disease. Autoimmun Rev (2009) 1.20
Regulatory NK cells in autoimmune disease. J Autoimmun (2012) 1.19
Genetic and immunologic considerations in autism. Neurobiol Dis (2002) 1.19